PD12-10 URINE COMPREHENSIVE GENOMIC PROFILING OF UROTHELIAL CARCINOMA PATIENTS UNDERGOING INTRAVESICAL THERAPY ENABLES DETECTION OF ACTIONABLE DNA MUTATIONS ASSOCIATED WITH DRUG RESPONSE AND RISK STRATIFICATION. (May 2022)